

Natalie Sampson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2072682/publications.pdf>

Version: 2024-02-01

34
papers

1,912
citations

279701

23
h-index

360920

35
g-index

35
all docs

35
docs citations

35
times ranked

3841
citing authors

#	ARTICLE	IF	CITATIONS
1	miRâ€17, miRâ€19b, miRâ€20a, and miRâ€106a are downâ€regulated in human aging. <i>Aging Cell</i> , 2010, 9, 291-296.	3.0	338
2	Mutation of the Na-K-Cl Co-Transporter Gene Slc12a2 Results in Deafness in Mice. <i>Human Molecular Genetics</i> , 1999, 8, 1579-1584.	1.4	154
3	Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. <i>Gerontology</i> , 2019, 65, 458-464.	1.4	153
4	ROS Signaling by NOX4 Drives Fibroblast-to-Myofibroblast Differentiation in the Diseased Prostatic Stroma. <i>Molecular Endocrinology</i> , 2011, 25, 503-515.	3.7	140
5	The ageing male reproductive tract. <i>Journal of Pathology</i> , 2007, 211, 206-218.	2.1	81
6	In vitro model systems to study androgen receptor signaling in prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R49-R64.	1.6	81
7	Re-evaluation of the Role of Calcium Homeostasis Endoplasmic Reticulum Protein (CHERP) in Cellular Calcium Signaling. <i>Journal of Biological Chemistry</i> , 2013, 288, 355-367.	1.6	77
8	A role for TSPO in mitochondrial Ca ²⁺ homeostasis and redox stress signaling. <i>Cell Death and Disease</i> , 2017, 8, e2896-e2896.	2.7	75
9	ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 27-39.	1.3	61
10	Identification of evolutionarily conserved genetic regulators of cellular aging. <i>Aging Cell</i> , 2010, 9, 1084-1097.	3.0	57
11	Therapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2012, 2012, 1-15.	1.9	53
12	Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1458.	1.8	53
13	Dysregulation of Dkkâ€3 expression in benign and malignant prostatic tissue. <i>Prostate</i> , 2008, 68, 540-547.	1.2	51
14	Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. <i>Cancer Letters</i> , 2022, 530, 156-169.	3.2	49
15	Inhibition of Nox4â€dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromalâ€mediated protumorigenic interactions. <i>International Journal of Cancer</i> , 2018, 143, 383-395.	2.3	48
16	Redox Signaling as a Therapeutic Target to Inhibit Myofibroblast Activation in Degenerative Fibrotic Disease. <i>BioMed Research International</i> , 2014, 2014, 1-14.	0.9	46
17	The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. <i>Cancer Letters</i> , 2015, 367, 113-121.	3.2	46
18	Attenuated Proliferation and Trans-Differentiation of Prostatic Stromal Cells Indicate Suitability of Phosphodiesterase Type 5 Inhibitors for Prevention and Treatment of Benign Prostatic Hyperplasia. <i>Endocrinology</i> , 2010, 151, 3975-3984.	1.4	44

#	ARTICLE	IF	CITATIONS
19	SF4 and SFRS14, two related putative splicing factors on human chromosome 19p13.11. <i>Gene</i> , 2003, 305, 91-100.	1.0	29
20	Stromal Insulin-Like Growth Factor Binding Protein 3 (IGFBP3) Is Elevated in the Diseased Human Prostate and Promotes ex Vivo Fibroblast-to-Myofibroblast Differentiation. <i>Endocrinology</i> , 2013, 154, 2586-2599.	1.4	29
21	Phosphodiesterase Type 5 Inhibition Reverts Prostate Fibroblast-to-Myofibroblast Trans-Differentiation. <i>Endocrinology</i> , 2012, 153, 5546-5555.	1.4	28
22	GPR30 Promotes Prostate Stromal Cell Activation via Suppression of ER α Expression and Its Downstream Signaling Pathway. <i>Endocrinology</i> , 2016, 157, 3023-3035.	1.4	27
23	Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer. <i>Prostate</i> , 2013, 73, 1441-1452.	1.2	26
24	PAGE4 Positivity Is Associated with Attenuated AR Signaling and Predicts Patient Survival in Hormone-Naive Prostate Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1443-1454.	1.9	24
25	Human chorionic gonadotropin (hCG) in the male reproductive tract. <i>Molecular and Cellular Endocrinology</i> , 2007, 260-262, 190-196.	1.6	23
26	Comparative genomic sequencing reveals a strikingly similar architecture of a conserved syntenic region on human chromosome 11p15.3 (including gene ST5) and mouse chromosome 7. <i>Cytogenetic and Genome Research</i> , 2001, 93, 284-290.	0.6	18
27	p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2020, 27, 187-198.	1.6	17
28	Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1 α Upregulation in PTEN Negative Prostate Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2129.	1.8	15
29	MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors. <i>American Journal of Pathology</i> , 2021, 191, 1094-1107.	1.9	14
30	Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by <i>Cimicifuga racemosa</i> extract BNO-1055. <i>Phytomedicine</i> , 2013, 20, 1306-1314.	2.3	13
31	Seminal plasma enhances and accelerates progesterone-induced decidualisation of human endometrial stromal cells. <i>Reproduction, Fertility and Development</i> , 2012, 24, 517.	0.1	12
32	GAGEC1, a cancer/testis associated antigen family member, is a target of TGF- β 1 in age-related prostatic disease. <i>Mechanisms of Ageing and Development</i> , 2007, 128, 64-66.	2.2	9
33	NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer. <i>Tumor Biology</i> , 2019, 41, 101042831983000.	0.8	8
34	Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene Signature Predicts Clinical Progression in a Subgroup of ERG-positive Prostate Cancers. <i>Eur Urol</i> 2013;64:941-50. <i>European Urology</i> , 2014, 65, e102-e103.	0.9	4